Innate Pharma (IPHA) EBT Margin (2019 - 2025)
Innate Pharma's (IPHA) quarterly EBT Margin came in at 1764.51% in Q4 2025, down 137257.0% YoY from N/an in Q4 2024, and down 350.2% on a QoQ basis from 391.94% in Q4 2024.
Innate Pharma (IPHA) EBT Margin (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of EBT Margin data on file, last reported at 1764.51% in Q4 2025.
- Quarterly EBT Margin fell 137257.0% year-over-year to 1764.51% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 197.46% (down 12289.0% YoY) and the FY2025 annual result came in at 546.11%, down 30024.0% from the prior year.
- EBT Margin slipped to 1764.51% in Q4 2025, from 391.94% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1.61% in Q2 2023 to a low of 1764.51% in Q4 2025.
- A 5-year average of 408.99% and a median of 298.61% in 2024 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin jumped 39482 bps — and 2025, when it plunged 137257 bps.
- Tracing IPHA's EBT Margin over 5 years: stood at 394.86% in 2021, then soared by 100 bps to 0.03% in 2022, then plunged by 43927 bps to 14.59% in 2023, then plunged by 2587 bps to 391.94% in 2024, then sank by 350 bps to 1764.51% in 2025.
- The last three EBT Margin figures came in at 1764.51% (Q4 2025), 391.94% (Q4 2024), and 298.61% (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Innate Pharma | 202.03 Mn | 202.03 Mn | - | -1,764.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,764.51% |
| Dec 31, 2024 | -391.94% |
| Jun 30, 2024 | -298.61% |
| Dec 31, 2023 | -14.59% |
| Jun 30, 2023 | 1.61% |
| Dec 31, 2022 | -0.03% |
| Dec 31, 2021 | -394.86% |
| Dec 31, 2020 | -1.48% |
| Dec 31, 2019 | -30.10% |